• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·000100.KS
Share

Yuhan Corporation Stocks

₩ 71900Last Updated 23.06.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

₩ 3.64B

₩ 71900
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for both domestic and international markets. Its extensive product portfolio encompasses a wide array of prescription pharmaceuticals (ETC), addressing therapeutic areas such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, and hormonal therapies. Notable offerings include Revanex, an acid pump antagonist designed for treating peptic ulcers and gastritis-related mucosal injury. Beyond prescription drugs, Yuhan Corporation provides a diverse range of over-the-counter (OTC) medications, including vitamins, mineral supplements, hepatopathy treatments, tonics, and drugs for respiratory, alimentary, dermatological, and pain relief applications. The company also extends its reach into consumer health and household goods, producing items like bleaches, detergents, pesticides, and oral care products. Further diversifying its operations, Yuhan is involved in the dental sector, supplying implants, equipment, consumables, and dental care solutions, and manufactures veterinary medical supplies for livestock, aquatic species, and companion animals. Additionally, it offers contract manufacturing services to other businesses.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA, overvalue

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 000100.KS is 137059 and suggests 86.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.06.2026 07:00

Alphabet will be added to the Dow Jones Blue Chip Index. Its stock price has doubled over the past year

24.06.2026 01:47

The boom in the prediction market has prompted Meta to create its own app — NYT

24.06.2026 01:09

The Nasdaq fell 2%, with volatility hitting a two-year high: a look back at the day's sell-off in the tech sector

24.06.2026 00:50

The dollar rose to its highest level since November: Traders are betting on a Fed rate hike

23.06.2026 23:45

Cathie Wood's company bought SpaceX shares on the day the stock fell 16%. Should you do the same?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026